Company intelligence / Profile preview
Kenai Therapeutics
Cambridge, Massachusetts, United Stateskenaitx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Kenai Therapeutics develops off-the-shelf, iPSC-derived dopamine neuron replacement therapies as potentially curative treatments for neurological conditions. Its lead candidate RNDP‑001 has shown robust survival and behavioral rescue in preclinical models of Parkinson’s disease. The company recently raised $82 million in Series A financing to support IND submission and a Phase I proof-of-concept trial for RNDP‑001 targeting both idiopathic and inherited forms of Parkinson’s disease. Additional pipeline programs are anticipated but not yet disclosed.
- Therapeutic areas
- Neurology
- Modalities
- Allogeneic cell therapy (iPSC-derived)Induced pluripotent stem cell (iPSC) technology
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Fujifilm Cellular Dynamics Inc. – manufacturing/development services partnerLilly Gateway Labs – research facility location
Beyond the preview
Go deeper on Kenai Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kenai Therapeutics.